- $2.28m
- -$12.65m
- $34.76m
Annual income statement for C3is, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 20-F | 6-K |
| Standards: | USG | USG | USG | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 16.1 | 28.7 | 42.3 | 34.8 |
| Cost of Revenue | ||||
| Gross Profit | 10.3 | 16.1 | 19.8 | 10.9 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | -2 | 18.3 | 32.2 | 33.4 |
| Operating Profit | 18.1 | 10.4 | 10.1 | 1.36 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | 18 | 9.29 | -2.75 | 10.5 |
| Net Income After Taxes | 18 | 9.29 | -2.75 | 10.5 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 18 | 9.29 | -2.75 | 10.5 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Dilution Adjustment | ||||
| Diluted Net Income | 18 | 9.22 | -8.09 | 4.18 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 7,138 | 18,921 | -515 | 12 |